Mylan Announces Management of Specialty Business...( PITTSBURGH Oct. 2 /- Mylan Inc. (...),Health

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today the management transition plan at Dey L.P., Mylan's specialty pharmaceutical business. As part of Merck Generics' integration into Mylan, Carolyn Myers, Ph.D. has been appointed President-Elect of Dey and Christy Taylor has been promoted to Chief Operating Officer, Dey.

Dr. Myers currently serves as President of Mylan Technologies, a position she has held since February 2006. While at Mylan Technologies, Dr. Myers has overseen the design, development and manufacture of Mylan's transdermal drug delivery system. She first joined Mylan in 2003 as Vice President of Branded Business Development and Strategic Marketing. Prior to joining Mylan, Dr. Myers served as Global Director Cardiovascular at Pharmacia Inc.

Ms. Taylor initially joined Dey in 2002, most recently serving as Executive Vice President of sales, marketing, business development and government affairs. In this role, she has directed marketing, Dey's three sales teams, sales operations, as well as the business development activities of the Company. In addition, Ms. Taylor has led the government affairs efforts on behalf of Dey. Before joining Dey, Ms. Taylor was vice chairman of Nelson Professional Sales, a provider of integrated selling solutions to the pharmaceutical industry.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Carolyn has been a valuable addition to the Mylan team since joining us four years ago to oversee our brand development strategy and, most recently, our extremely successful transdermal business. Her strong leadership skills and balanced background in science, marketing and business development make her ideally suited to lead Mylan
'/>"/>